Illuminating Myelodysplastic syndromes

9 July 2019

By Dr Nicola Davies

Myelodysplastic syndromes (MDS) are a group of disorders that arise from the inadequate functioning of the bone marrow (the spongy material in bones with stem cells), particularly in blood cell production.1 It is considered a form of blood cancer and stems from a lack or abnormal presentation of blood cells. In 2016, worldwide incidence of MDS was between 0.22-13.2 per 100,000 people across all ages, genders and ethnicities.2 Here is a look at MDS, its treatment, and pharma’s role in improving the quality of life of patients with this condition, says Dr Nicola Davies in her exclusive column for The Pharma Letter.

What are Myelodysplastic syndromes?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK